Home / Providers / Hers

Provider fact sheet · dataset v2026.08.14-4 · last touched —

Hers: GLP-1 programs, prices, and verification status (2026)

Quick take

Hers is a unverified entry in our universe. Hims' sister brand under the same parent (HIMS), historically marketing the same compounded programs to women; the March 2026 Novo partnership applies across the house.

Programs and pricing, in plain sentences

Compounded tirzepatide — status: third-party reported. ~$299/mo per an April 2026 aggregator comparison; post-Novo-pivot lane status unclear — verify what the current checkout actually offers before relying on this figure.

Every figure above carries its status — operator claims come from the provider, reported from third parties we cite, verified only after our own checkout walk. Machine-readable version: providers.json.

Update — August 14, 2026: A reported price lands: ~$299/mo compounded tirzepatide per the April 2026 tirzepatide.us.com comparison — with the house-wide caveat that the Hims/Hers platform pivoted to brand-forward semaglutide after the March 2026 Novo partnership, so treat compounded-tirzepatide listings under this brand as legacy-lane figures pending the platform's current checkout.

Verification status and open items

Current status: unverified, last touched —. Open verification items: dispensing pharmacy identity, state coverage map, cancellation terms. Source on file: universe scan. Corrections land within 48 hours via the public log — if your checkout contradicts this page, that report changes the dataset.

How Hers fits the market

Hims' sister brand under the same parent (HIMS), historically marketing the same compounded programs to women; the March 2026 Novo partnership applies across the house. Treat the compounded pricing as historical pending re-verification, and read the Hims sheet for the transition detail. Where it lands overall: the price ladder, the category winners, and the program finder all compute from the same dataset this page renders.

Visit Hers ↗

Advertising disclosure: outbound provider links may be commission-bearing; our partner relationship with NexLife is disclosed on the ownership page and never alters statuses or rankings.